“Car-T and Bispecific Antibodies for Refractory Non-Hodgkin Lymphoma: Long-Term Safety and Autoimmune Sequelae”., JOC, vol. 24, no. 6s, pp. 805–820, Sep. 2025, doi: 10.64149/.